Roche's New Obesity Drug Drops 15.5% Body Weight, Escalating the GLP-1 War with Lilly and Novo

Roche's experimental obesity drug enicepatide delivered 15.5% weight loss in a Phase 2 diabetes trial — a result that could reshape the competitive landscape dominated by Eli Lilly and Novo Nordisk. Patients on the highest 24-milligram dose also saw HbA1c drop by 2.65 percentage points after 48 weeks, with Roche stating weight loss had not yet plateaued.

The once-weekly injectable targets both GLP-1 and GIP hormones — the same dual mechanism behind Lilly's...